

# Christa E MÃ¼ller

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2400977/publications.pdf>

Version: 2024-02-01

465  
papers

23,532  
citations

6250

80  
h-index

17580

121  
g-index

482  
all docs

482  
docs citations

482  
times ranked

19630  
citing authors

#	ARTICLE	IF	CITATIONS
1	3CL Protease Inhibitors with an Electrophilic Arylketone Moiety as Anti-SARS-CoV-2 Agents. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 2926-2939.	2.9	75
2	Andrographolide Derivatives Target the KEAP1/NRF2 Axis and Possess Potent Anti-SARS-CoV-2 Activity. <i>ChemMedChem</i> , 2022, 17, e202100732.	1.6	6
3	Development of high-affinity fluorinated ligands for cannabinoid subtype 2 receptor, and in vitro evaluation of a radioactive tracer for imaging. <i>European Journal of Medicinal Chemistry</i> , 2022, 232, 114138.	2.6	5
4	Structure-Activity Relationship of 3-Methylcytidine-5'- $\beta$ , $\gamma$ -methylendiphosphates as CD73 Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 2409-2433.	2.9	5
5	GPR18-Mediated Relaxation of Human Isolated Pulmonary Arteries. <i>International Journal of Molecular Sciences</i> , 2022, 23, 1427.	1.8	7
6	P2X4 and P2X7 are essential players in basal T cell activity and Ca <sup>2+</sup> signaling milliseconds after T cell activation. <i>Science Advances</i> , 2022, 8, eabl9770.	4.7	20
7	CD73 controls ocular adenosine levels and protects retina from light-induced phototoxicity. <i>Cellular and Molecular Life Sciences</i> , 2022, 79, 152.	2.4	5
8	International Union of Basic and Clinical Pharmacology. CXII: Adenosine Receptors: A Further Update. <i>Pharmacological Reviews</i> , 2022, 74, 340-372.	7.1	67
9	Discovery of P2Y <sub>2</sub> Receptor Antagonist Scaffolds through Virtual High-Throughput Screening. <i>Journal of Chemical Information and Modeling</i> , 2022, 62, 1538-1549.	2.5	6
10	Single Stabilizing Point Mutation Enables High-Resolution Co-Crystal Structures of the Adenosine A <sub>2A</sub> Receptor with Preladenant Conjugates. <i>Angewandte Chemie - International Edition</i> , 2022, 61, .	7.2	14
11	Heterotrimeric G Protein $\beta$ -Subunits - Structures, Peptide-Derived Inhibitors, and Mechanisms. <i>Current Medicinal Chemistry</i> , 2022, 29, 6359-6378.	1.2	7
12	<i>ACS Pharmacology &amp; Translational Science</i> in 2022. <i>ACS Pharmacology and Translational Science</i> , 2022, 5, 1-2.	2.5	0
13	Chemistry and Analysis of Organic Compounds in Dinosaurs. <i>Biology</i> , 2022, 11, 670.	1.3	11
14	Agonist-Dependent Coupling of the Promiscuous Adenosine A <sub>2B</sub> Receptor to G $\beta$ Protein Subunits. <i>ACS Pharmacology and Translational Science</i> , 2022, 5, 373-386.	2.5	8
15	Innentitelbild: Eine einzige stabilisierende Punktmutation ermöglicht hochauflösende Co-Kristallstrukturen des Adenosin A <sub>2A</sub> -Rezeptors mit Preladenant-Konjugaten (Angew.) <i>TJ ETOP</i> 1 0.784314 rgBT	7.2	14
16	Caffeine intake exerts dual genome-wide effects on hippocampal metabolism and learning-dependent transcription. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	22
17	Irreversible Antagonists for the Adenosine A <sub>2B</sub> Receptor. <i>Molecules</i> , 2022, 27, 3792.	1.7	6
18	Small-Molecule Thioesters as SARS-CoV-2 Main Protease Inhibitors: Enzyme Inhibition, Structure-Activity Relationships, Antiviral Activity, and X-ray Structure Determination. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 9376-9395.	2.9	35

#	ARTICLE	IF	CITATIONS
19	Agonists, Antagonists, and Modulators of P2X7 Receptors. <i>Methods in Molecular Biology</i> , 2022, , 31-52.	0.4	8
20	Apoptotic brown adipocytes enhance energy expenditure via extracellular inosine. <i>Nature</i> , 2022, 609, 361-368.	13.7	53
21	Sphingosine-1-phosphate induces migration of microglial cells via activation of volume-sensitive anion channels, ATP secretion and activation of purinergic receptors. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2021, 1868, 118915.	1.9	13
22	Update of P2X receptor properties and their pharmacology: IUPHAR Review 30. <i>British Journal of Pharmacology</i> , 2021, 178, 489-514.	2.7	165
23	Medicinal chemistry of P2 and adenosine receptors: Common scaffolds adapted for multiple targets. <i>Biochemical Pharmacology</i> , 2021, 187, 114311.	2.0	29
24	Sulfated Polysaccharides from Macroalgae Are Potent Dual Inhibitors of Human ATP-Hydrolyzing Ectonucleotidases NPP1 and CD39. <i>Marine Drugs</i> , 2021, 19, 51.	2.2	8
25	Thioesterase-mediated side chain transesterification generates potent Gq signaling inhibitor FR900359. <i>Nature Communications</i> , 2021, 12, 144.	5.8	32
26	A Cellular Assay for the Identification and Characterization of Connexin Gap Junction Modulators. <i>International Journal of Molecular Sciences</i> , 2021, 22, 1417.	1.8	7
27	Chemistry of porphyrins in fossil plants and animals. <i>RSC Advances</i> , 2021, 11, 7552-7563.	1.7	26
28	Macrocyclic Gq Protein Inhibitors FR900359 and/or YM-254890â€œFit for Translation?. <i>ACS Pharmacology and Translational Science</i> , 2021, 4, 888-897.	2.5	17
29	Thermal proteome profiling identifies the membrane-bound purinergic receptor P2X4 as a target of the autophagy inhibitor indophagolin. <i>Cell Chemical Biology</i> , 2021, 28, 1750-1757.e5.	2.5	22
30	Effects of GPR18 Ligands on Body Weight and Metabolic Parameters in a Female Rat Model of Excessive Eating. <i>Pharmaceuticals</i> , 2021, 14, 270.	1.7	7
31	Targeting the Main Protease of SARSâ€œCoVâ€œ2: From the Establishment of High Throughput Screening to the Design of Tailored Inhibitors. <i>Angewandte Chemie - International Edition</i> , 2021, 60, 10423-10429.	7.2	95
32	Die Hauptprotease von SARSâ€œCoVâ€œ2 als Zielstruktur: Von der Etablierung eines Hochdurchsatzâ€œScreenings zum Design maßgeschneiderter Inhibitoren. <i>Angewandte Chemie</i> , 2021, 133, 10515-10521.	1.6	3
33	PSB 603 â€œa known selective adenosine A2B receptor antagonist â€œ has anti-inflammatory activity in mice. <i>Biomedicine and Pharmacotherapy</i> , 2021, 135, 111164.	2.5	21
34	Accelerating Translation of Innovative Drugs from Bench to Patients: ACS Pharmacology & Translational Science to Evolve, Grow, and Bridge the Gap between Chemistry and Biology in Drug Research and Development. <i>ACS Pharmacology and Translational Science</i> , 2021, 4, 1026-1027.	2.5	2
35	Synthesis of Novel Fluorinated Xanthine Derivatives with High Adenosine A2B Receptor Binding Affinity. <i>Pharmaceuticals</i> , 2021, 14, 485.	1.7	1
36	Adenosine A <sub>2A</sub> /A <sub>1</sub> Receptor Antagonists Enabling Additional H <sub>3</sub> Receptor Antagonism for the Treatment of Parkinsonâ€™s Disease. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 8246-8262.	2.9	6

#	ARTICLE	IF	CITATIONS
37	Iodine-catalyzed electrophilic substitution of indoles: Synthesis of (un)symmetrical diindolylmethanes with a quaternary carbon center. <i>Beilstein Journal of Organic Chemistry</i> , 2021, 17, 1464-1475.	1.3	5
38	Feature-Based Molecular Networking for the Targeted Identification of G <sub>q</sub> -Inhibiting FR900359 Derivatives. <i>Journal of Natural Products</i> , 2021, 84, 1941-1953.	1.5	7
39	Europe Virtual Issue: Pharmacology and Translational Science in Europe. <i>ACS Pharmacology and Translational Science</i> , 2021, 4, 1264-1264.	2.5	0
40	Virtual Issue: Oncology, Immunology, and Immuno-oncology. <i>ACS Pharmacology and Translational Science</i> , 2021, 4, 1475.	2.5	0
41	The GPR18 Agonist PSB-KD-107 Exerts Endothelium-Dependent Vasorelaxant Effects. <i>Pharmaceuticals</i> , 2021, 14, 799.	1.7	7
42	Fintiamin: A diketopiperazine from the marine sponge-derived fungus <i>Eurotium</i> sp.. <i>Archiv Der Pharmazie</i> , 2021, 354, e2100206.	2.1	6
43	A group of cationic amphiphilic drugs activates MRGPRX2 and induces scratching behavior in mice. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 148, 506-522.e8.	1.5	29
44	New Drug Modalities in Medicinal Chemistry, Pharmacology, and Translational Science: Joint Virtual Special Issue by <i>Journal of Medicinal Chemistry</i> , <i>ACS Medicinal Chemistry Letters</i> , and <i>ACS Pharmacology &amp; Translational Science</i> . <i>Journal of Medicinal Chemistry</i> , 2021, 64, 13935-13936.	2.9	3
45	Recommended tool compounds and drugs for blocking P2X and P2Y receptors. <i>Purinergic Signalling</i> , 2021, 17, 633-648.	1.1	21
46	New Drug Modalities in Medicinal Chemistry, Pharmacology, and Translational Science: Joint Virtual Special Issue by <i>Journal of Medicinal Chemistry</i> , <i>ACS Medicinal Chemistry Letters</i> , and <i>ACS Pharmacology &amp; Translational Science</i> . <i>ACS Medicinal Chemistry Letters</i> , 2021, 12, 1508-1509.	1.3	2
47	New Drug Modalities in Medicinal Chemistry, Pharmacology, and Translational Science: Joint Virtual Special Issue by <i>Journal of Medicinal Chemistry</i> , <i>ACS Medicinal Chemistry Letters</i> , and <i>ACS Pharmacology &amp; Translational Science</i> . <i>ACS Pharmacology and Translational Science</i> , 2021, 4, 1712-1713.	2.5	0
48	THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: G protein-coupled receptors. <i>British Journal of Pharmacology</i> , 2021, 178, S27-S156.	2.7	337
49	Unraveling binding mechanism and kinetics of macrocyclic G <sub>12/13</sub> protein inhibitors. <i>Pharmacological Research</i> , 2021, 173, 105880.	3.1	10
50	Structure-activity relationships of agonists for the orphan G protein-coupled receptor GPR27. <i>European Journal of Medicinal Chemistry</i> , 2021, 225, 113777.	2.6	9
51	An experimental strategy to probe G <sub>q</sub> contribution to signal transduction in living cells. <i>Journal of Biological Chemistry</i> , 2021, 296, 100472.	1.6	22
52	Discovery of potent nucleotide pyrophosphatase/phosphodiesterase3 (NPP3) inhibitors with ancillary carbonic anhydrase inhibition for cancer (immuno)therapy. <i>RSC Medicinal Chemistry</i> , 2021, 12, 1187-1206.	1.7	5
53	A novel P2X <sub>2</sub> -dependent purinergic mechanism of enteric gliosis in intestinal inflammation. <i>EMBO Molecular Medicine</i> , 2021, 13, e12724.	3.3	35
54	CD73-mediated adenosine production by CD8 T cell-derived extracellular vesicles constitutes an intrinsic mechanism of immune suppression. <i>Nature Communications</i> , 2021, 12, 5911.	5.8	66

#	ARTICLE	IF	CITATIONS
55	2-Substituted thienotetrahydropyridine derivatives: Allosteric ectonucleotidase inhibitors. <i>Archiv Der Pharmazie</i> , 2021, 354, e2100300.	2.1	4
56	Involvement of GPR17 in Neuronal Fibre Outgrowth. <i>International Journal of Molecular Sciences</i> , 2021, 22, 11683.	1.8	3
57	Quantification of Degradation Products Formed during Heat Sterilization of Glucose Solutions by LC-MS/MS: Impact of Autoclaving Temperature and Duration on Degradation. <i>Pharmaceuticals</i> , 2021, 14, 1121.	1.7	10
58	Age-related shift in LTD is dependent on neuronal adenosine A2A receptors interplay with mGluR5 and NMDA receptors. <i>Molecular Psychiatry</i> , 2020, 25, 1876-1900.	4.1	129
59	An Agonist Radioligand for the Proinflammatory Lipid-Activated G Protein-Coupled Receptor GPR84 Providing Structural Insights. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 2391-2410.	2.9	21
60	Substituted 4-phenylthiazoles: Development of potent and selective A1, A3 and dual A1/A3 adenosine receptor antagonists. <i>European Journal of Medicinal Chemistry</i> , 2020, 186, 111879.	2.6	9
61	Design, synthesis and biological evaluation of suramin-derived dual antagonists of the proinflammatory G protein-coupled receptors P2Y2 and GPR17. <i>European Journal of Medicinal Chemistry</i> , 2020, 186, 111789.	2.6	10
62	Ligand binding and activation of UTP-activated G protein-coupled P2Y2 and P2Y4 receptors elucidated by mutagenesis, pharmacological and computational studies. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2020, 1864, 129501.	1.1	6
63	A2A and A2B adenosine receptors: The extracellular loop 2 determines high (A2A) or low affinity (A2B) for adenosine. <i>Biochemical Pharmacology</i> , 2020, 172, 113718.	2.0	24
64	Cell-permeable high-affinity tracers for G <sub>q</sub> proteins provide structural insights, reveal distinct binding kinetics and identify small molecule inhibitors. <i>British Journal of Pharmacology</i> , 2020, 177, 1898-1916.	2.7	21
65	Sensitive LC-MS/MS Method for the Quantification of Macrocyclic G <sub>q</sub> Protein Inhibitors in Biological Samples. <i>Frontiers in Chemistry</i> , 2020, 8, 833.	1.8	4
66	Update of P2Y receptor pharmacology: IUPHAR Review 27. <i>British Journal of Pharmacology</i> , 2020, 177, 2413-2433.	2.7	151
67	2-Substituted $\beta$ -Methylene-ADP Derivatives: Potent Competitive Ecto-5'-nucleotidase (CD73) Inhibitors with Variable Binding Modes. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 2941-2957.	2.9	37
68	Dissection of P2X4 and P2X7 Receptor Current Components in BV-2 Microglia. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8489.	1.8	15
69	Synthesis and structure-activity relationships of cerebroside analogues as substrates of cerebroside sulphotransferase and discovery of a competitive inhibitor. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2020, 35, 1503-1512.	2.5	4
70	Nucleotide Analog ARL67156 as a Lead Structure for the Development of CD39 and Dual CD39/CD73 Ectonucleotidase Inhibitors. <i>Frontiers in Pharmacology</i> , 2020, 11, 1294.	1.6	23
71	Nucleotide P2Y1 receptor agonists are in vitro and in vivo prodrugs of A1/A3 adenosine receptor agonists: implications for roles of P2Y1 and A1/A3 receptors in physiology and pathology. <i>Purinergic Signalling</i> , 2020, 16, 543-559.	1.1	17
72	Fluorescent Probes for Ecto-5'-nucleotidase (CD73). <i>ACS Medicinal Chemistry Letters</i> , 2020, 11, 2253-2260.	1.3	10

#	ARTICLE	IF	CITATIONS
73	Development of Anthraquinone Derivatives as Ectonucleoside Triphosphate Diphosphohydrolase (NTPDase) Inhibitors With Selectivity for NTPDase2 and NTPDase3. <i>Frontiers in Pharmacology</i> , 2020, 11, 1282.	1.6	12
74	Design, Synthesis and Biological Evaluation of Highly Potent Simplified Archazolids. <i>ChemMedChem</i> , 2020, 15, 1348-1363.	1.6	5
75	P2Y2 Receptor Promotes High-Fat Diet-Induced Obesity. <i>Frontiers in Endocrinology</i> , 2020, 11, 341.	1.5	23
76	Development of a Radiofluorinated Adenosine A2B Receptor Antagonist as Potential Ligand for PET Imaging. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3197.	1.8	3
77	Discovery of Tricyclic Xanthines as Agonists of the Cannabinoid-Activated Orphan G-Protein-Coupled Receptor GPR18. <i>ACS Medicinal Chemistry Letters</i> , 2020, 11, 2024-2031.	1.3	16
78	Novel, Dual Target-Directed Annelated Xanthine Derivatives Acting on Adenosine Receptors and Monoamine Oxidase B. <i>ChemMedChem</i> , 2020, 15, 772-786.	1.6	9
79	P2Y <sub>1</sub> -like nucleotide receptors” Structures, molecular modeling, mutagenesis, and oligomerization. <i>Wiley Interdisciplinary Reviews: Computational Molecular Science</i> , 2020, 10, e1464.	6.2	12
80	8-Benzylaminoxanthine scaffold variations for selective ligands acting on adenosine A2A receptors. Design, synthesis and biological evaluation. <i>Bioorganic Chemistry</i> , 2020, 101, 104033.	2.0	5
81	Synthesis of Novel Potent Archazolids: Pharmacology of an Emerging Class of Anticancer Drugs. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 1684-1698.	2.9	14
82	Discovery and Structure Relationships of Salicylanilide Derivatives as Potent, Non-acidic P2X1 Receptor Antagonists. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 6164-6178.	2.9	10
83	Computational Investigations on the Binding Mode of Ligands for the Cannabinoid-Activated G Protein-Coupled Receptor GPR18. <i>Biomolecules</i> , 2020, 10, 686.	1.8	13
84	Agonists and Antagonists for Purinergic Receptors. <i>Methods in Molecular Biology</i> , 2020, 2041, 45-64.	0.4	37
85	Recombinant expression of ecto-nucleotide pyrophosphatase/phosphodiesterase 4 (NPP4) and development of a luminescence-based assay to identify inhibitors. <i>Analytical Biochemistry</i> , 2020, 603, 113774.	1.1	14
86	Extracellular adenosine reversibly inhibits the activation of human regulatory T cells and negatively influences the achievement of the operational tolerance in liver transplantation. <i>American Journal of Transplantation</i> , 2019, 19, 48-61.	2.6	19
87	Tools and Drugs for Purine-Binding Targets” Important Players in Inflammation and Cancer. <i>Proceedings (mdpi)</i> , 2019, 22, .	0.2	0
88	Decarboxylative Coupling Reaction of $\alpha$ -Indolylacetic Acids with Indole, Azaindole, Benzimidazole and Indazole Derivatives. <i>Advanced Synthesis and Catalysis</i> , 2019, 361, 4286-4293.	2.1	20
89	X-ray Crystal Structure Guides the Way to Subnanomolar Competitive Ecto <sup>5</sup> -Nucleotidase (CD73) Inhibitors for Cancer Immunotherapy. <i>Advanced Therapeutics</i> , 2019, 2, 1900075.	1.6	33
90	Identification of aurintricarboxylic acid as a potent allosteric antagonist of P2X1 and P2X3 receptors. <i>Neuropharmacology</i> , 2019, 158, 107749.	2.0	38

#	ARTICLE	IF	CITATIONS
91	Structural and Conformational Studies on Carboxamides of 5,6-Diaminouracils—Precursors of Biologically Active Xanthine Derivatives. <i>Molecules</i> , 2019, 24, 2168.	1.7	2
92	Memory deficits induced by chronic cannabinoid exposure are prevented by adenosine A2AR receptor antagonism. <i>Neuropharmacology</i> , 2019, 155, 10-21.	2.0	21
93	Identification of adenine-N9-(methoxy)ethyl- $\beta$ -bisphosphonate as NPP1 inhibitor attenuates NPPase activity in human osteoarthritic chondrocytes. <i>Purinergic Signalling</i> , 2019, 15, 247-263.	1.1	6
94	Structure–Activity Relationship of Purine and Pyrimidine Nucleotides as Ecto-5'-Nucleotidase (CD73) Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 3677-3695.	2.9	53
95	Adenosine Receptor Antagonists with Picomolar Potency. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 4032-4055.	2.9	17
96	Fast, Efficient, and Versatile Synthesis of 6-amino-5-carboxamidouracils as Precursors for 8-Substituted Xanthines. <i>Frontiers in Chemistry</i> , 2019, 7, 56.	1.8	14
97	Coordination of capsule assembly and cell wall biosynthesis in <i>Staphylococcus aureus</i> . <i>Nature Communications</i> , 2019, 10, 1404.	5.8	66
98	Novel multi-target directed ligands based on annelated xanthine scaffold with aromatic substituents acting on adenosine receptor and monoamine oxidase B. Synthesis, in vitro and in silico studies. <i>Bioorganic and Medicinal Chemistry</i> , 2019, 27, 1195-1210.	1.4	17
99	Development of Chromen-4-one Derivatives as (Ant)agonists for the Lipid-Activated G Protein-Coupled Receptor GPR55 with Tunable Efficacy. <i>ACS Omega</i> , 2019, 4, 4276-4295.	1.6	9
100	Modulating P1 Adenosine Receptors in Disease Progression of SOD1G93A Mutant Mice. <i>Neurochemical Research</i> , 2019, 44, 1037-1042.	1.6	7
101	Adenine-(methoxy)-ethoxy- $\beta$ -dithio-triphosphate inhibits pathologic calcium pyrophosphate deposition in osteoarthritic human chondrocytes. <i>Organic and Biomolecular Chemistry</i> , 2019, 17, 9913-9923.	1.5	3
102	Elucidating the active $\mu$ -opioid receptor crystal structure with peptide and small-molecule agonists. <i>Science Advances</i> , 2019, 5, eaax9115.	4.7	81
103	Chromenones as Multineurotargeting Inhibitors of Human Enzymes. <i>ACS Omega</i> , 2019, 4, 22161-22168.	1.6	17
104	Koala and Wombat Gammaherpesviruses Encode the First Known Viral NTPDase Homologs and Are Phylogenetically Divergent from All Known Gammaherpesviruses. <i>Journal of Virology</i> , 2019, 93, .	1.5	2
105	Investigation on 2,3-Substituted ATP Derivatives and Analogs as Novel P2X3 Receptor Antagonists. <i>ACS Medicinal Chemistry Letters</i> , 2019, 10, 493-498.	1.3	8
106	Soluble and membrane-bound adenylate kinase and nucleotidases augment ATP-mediated inflammation in diabetic retinopathy eyes with vitreous hemorrhage. <i>Journal of Molecular Medicine</i> , 2019, 97, 341-354.	1.7	21
107	Diabetes-induced Neuropathic Mechanical Hyperalgesia Depends on P2X4 Receptor Activation in Dorsal Root Ganglia. <i>Neuroscience</i> , 2019, 398, 158-170.	1.1	38
108	Antithrombotic P2Y12 receptor antagonists: recent developments in drug discovery. <i>Drug Discovery Today</i> , 2019, 24, 325-333.	3.2	41

#	ARTICLE	IF	CITATIONS
109	P2Y receptors (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database. IUPHAR/BPS Guide To Pharmacology CITE, 2019, 2019, .	0.2	6
110	Synthesis and structure-activity relationships of quinolinone and quinoline-based P2X7 receptor antagonists and their anti-sphere formation activities in glioblastoma cells. European Journal of Medicinal Chemistry, 2018, 151, 462-481.	2.6	24
111	Genome Editing in Neuroepithelial Stem Cells to Generate Human Neurons with High Adenosine-Releasing Capacity. Stem Cells Translational Medicine, 2018, 7, 477-486.	1.6	8
112	Mechanism underlying the contractile activity of UTP in the mammalian heart. European Journal of Pharmacology, 2018, 830, 47-58.	1.7	12
113	Fluorescent-Labeled Selective Adenosine A <sub>2B</sub> Receptor Antagonist Enables Competition Binding Assay by Flow Cytometry. Journal of Medicinal Chemistry, 2018, 61, 4301-4316.	2.9	24
114	Tools and drugs for uracil nucleotide-activated P2Y receptors. , 2018, 190, 24-80.		42
115	Pharmacological evaluation of new constituents of "Spice" synthetic cannabinoids based on indole, indazole, benzimidazole and carbazole scaffolds. Forensic Toxicology, 2018, 36, 385-403.	1.4	88
116	6-(Ar)Alkylamino-Substituted Uracil Derivatives: Lipid Mimetics with Potent Activity at the Orphan G Protein-Coupled Receptor 84 (GPR84). ACS Omega, 2018, 3, 3365-3383.	1.6	30
117	Adenosine A <sub>2A</sub> receptor agonists with potent antiplatelet activity. Platelets, 2018, 29, 292-300.	1.1	20
118	Structural characterization and pharmacological evaluation of the new synthetic cannabinoid CUMYL-PEGACLONE. Drug Testing and Analysis, 2018, 10, 597-603.	1.6	37
119	Mechanisms of the action of adenosine on anti-allergic effects in mast cells. Immunity, Inflammation and Disease, 2018, 6, 97-105.	1.3	6
120	Heterologous Expression, Biosynthetic Studies, and Ecological Function of the Selective Gq Signaling Inhibitor FR900359. Angewandte Chemie - International Edition, 2018, 57, 836-840.	7.2	57
121	Heterologe Expression, Biosynthese und Ökologische Funktion des selektiven Gq-Signaltransduktionsinhibitors FR900359. Angewandte Chemie, 2018, 130, 844-849.	1.6	5
122	Structural Mapping of Adenosine Receptor Mutations: Ligand Binding and Signaling Mechanisms. Trends in Pharmacological Sciences, 2018, 39, 75-89.	4.0	64
123	Development of a selective and highly sensitive fluorescence assay for nucleoside triphosphate diphosphohydrolase1 (NTPDase1, CD39). Analyst, The, 2018, 143, 5417-5430.	1.7	12
124	Adenosine A <sub>2A</sub> receptor ligand recognition and signaling is blocked by A <sub>2B</sub> receptors. Oncotarget, 2018, 9, 13593-13611.	0.8	77
125	Cyclopropane-Containing Fatty Acids from the Marine Bacterium Labrenzia sp. 011 with Antimicrobial and GPR84 Activity. Marine Drugs, 2018, 16, 369.	2.2	25
126	Structure-activity relationships of imidazothiazinones and analogs as antagonists of the cannabinoid-activated orphan G protein-coupled receptor GPR18. European Journal of Medicinal Chemistry, 2018, 155, 381-397.	2.6	22



#	ARTICLE	IF	CITATIONS
127	Tritium-labeled agonists as tools for studying adenosine A2B receptors. <i>Purinergic Signalling</i> , 2018, 14, 223-233.	1.1	16
128	Applying Molecular Networking for the Detection of Natural Sources and Analogues of the Selective Gq Protein Inhibitor FR900359. <i>Journal of Natural Products</i> , 2018, 81, 1628-1635.	1.5	27
129	Medicinal Chemistry of A2B Adenosine Receptors. , 2018, , 137-168.		12
130	Beneficial Effect of a Selective Adenosine A2A Receptor Antagonist in the APP <sup>swE</sup> /PS1 <sup>dE9</sup> Mouse Model of Alzheimer's Disease. <i>Frontiers in Molecular Neuroscience</i> , 2018, 11, 235.	1.4	72
131	3-(2-Carboxyethyl)indole-2-carboxylic Acid Derivatives: Structural Requirements and Properties of Potent Agonists of the Orphan G Protein-Coupled Receptor GPR17. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 8136-8154.	2.9	19
132	Understanding the Role of Adenosine A2AR Heteroreceptor Complexes in Neurodegeneration and Neuroinflammation. <i>Frontiers in Neuroscience</i> , 2018, 12, 43.	1.4	44
133	Preyssler's Polyoxoanions [Na <sub>5</sub> W <sub>30</sub> O <sub>110</sub> ] <sup>14-</sup> and [Ag <sub>5</sub> W <sub>30</sub> O <sub>110</sub> ] <sup>14-</sup> : Microwave-Assisted Synthesis, Structure, and Biological Activity. <i>Zeitschrift Fur Anorganische Und Allgemeine Chemie</i> , 2018, 644, 752-758.	0.6	17
134	General Synthesis of Unsymmetrical 3,3'-Diindolylmethane Derivatives. <i>Journal of Organic Chemistry</i> , 2018, 83, 9902-9913.	1.7	35
135	Probing Substituents in the 1- and 3-Position: Tetrahydropyrazino-Annulated Water-Soluble Xanthine Derivatives as Multi-Target Drugs With Potent Adenosine Receptor Antagonistic Activity. <i>Frontiers in Chemistry</i> , 2018, 6, 206.	1.8	8
136	Radiosynthesis and in vivo evaluation of a fluorine-18 labeled pyrazine based radioligand for PET imaging of the adenosine A2B receptor. <i>Bioorganic and Medicinal Chemistry</i> , 2018, 26, 4650-4663.	1.4	17
137	Molecular and functional interaction between GPR18 and cannabinoid CB2 G-protein-coupled receptors. Relevance in neurodegenerative diseases. <i>Biochemical Pharmacology</i> , 2018, 157, 169-179.	2.0	47
138	Tricyclic xanthine derivatives containing a basic substituent: adenosine receptor affinity and drug-related properties. <i>MedChemComm</i> , 2018, 9, 951-962.	3.5	9
139	Interaction of Approved Drugs with Synaptic Vesicle Protein 2A. <i>Archiv Der Pharmazie</i> , 2017, 350, 1700003.	2.1	9
140	Chronic and acute adenosine A2A receptor blockade prevents long-term episodic memory disruption caused by acute cannabinoid CB1 receptor activation. <i>Neuropharmacology</i> , 2017, 117, 316-327.	2.0	37
141	Prasugrel suppresses development of lithium-induced nephrogenic diabetes insipidus in mice. <i>Purinergic Signalling</i> , 2017, 13, 239-248.	1.1	10
142	Nucleotide pyrophosphatase/phosphodiesterase 1 (NPP1) and its inhibitors. <i>MedChemComm</i> , 2017, 8, 823-840.	3.5	80
143	Diindolylmethane Derivatives: Potent Agonists of the Immunostimulatory Orphan G Protein-Coupled Receptor GPR84. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 3636-3655.	2.9	81
144	Nanodiscs for INPHARMA NMR Characterization of GPCRs: Ligand Binding to the Human A2A Adenosine Receptor. <i>Angewandte Chemie</i> , 2017, 129, 5844-5848.	1.6	3

#	ARTICLE	IF	CITATIONS
145	Nanodiscs for INPHARMA NMR Characterization of GPCRs: Ligand Binding to the Human A2A Adenosine Receptor. <i>Angewandte Chemie - International Edition</i> , 2017, 56, 5750-5754.	7.2	16
146	Expression of Ecto-nucleoside Triphosphate Diphosphohydrolases-2 and -3 in the Enteric Nervous System Affects Inflammation in Experimental Colitis and Crohn's Disease. <i>Journal of Crohn's and Colitis</i> , 2017, 11, 1113-1123.	0.6	17
147	Development of Potent and Selective Antagonists for the UTP-Activated P2Y <sub>4</sub> Receptor. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 3020-3038.	2.9	33
148	The promiscuous ectonucleotidase NPP1: molecular insights into substrate binding and hydrolysis. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2017, 1861, 603-614.	1.1	36
149	Quantification of green fluorescent protein-(GFP-) tagged membrane proteins by capillary gel electrophoresis. <i>Analyst, The</i> , 2017, 142, 3648-3655.	1.7	6
150	Targeted inhibition of G <sub>q</sub> signaling induces airway relaxation in mouse models of asthma. <i>Science Translational Medicine</i> , 2017, 9, .	5.8	50
151	Molecular Recognition of Agonists and Antagonists by the Nucleotide-Activated G Protein-Coupled P2Y <sub>2</sub> Receptor. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 8425-8440.	2.9	27
152	Angiotensin II type 1/adenosine A <sub>2A</sub> receptor oligomers: a novel target for tardive dyskinesia. <i>Scientific Reports</i> , 2017, 7, 1857.	1.6	11
153	GPR55: A therapeutic target for Parkinson's disease?. <i>Neuropharmacology</i> , 2017, 125, 319-332.	2.0	67
154	Characterization of P2X <sub>4</sub> receptor agonists and antagonists by calcium influx and radioligand binding studies. <i>Biochemical Pharmacology</i> , 2017, 125, 41-54.	2.0	47
155	Synthesis, characterization, and in vitro evaluation of the selective P2Y <sub>2</sub> receptor antagonist AR-C118925. <i>Purinergic Signalling</i> , 2017, 13, 89-103.	1.1	56
156	P2Y <sub>2</sub> receptor modulates shear stress-induced cell alignment and actin stress fibers in human umbilical vein endothelial cells. <i>Cellular and Molecular Life Sciences</i> , 2017, 74, 731-746.	2.4	24
157	Treatment with A <sub>2A</sub> receptor antagonist KW6002 and caffeine intake regulate microglia reactivity and protect retina against transient ischemic damage. <i>Cell Death and Disease</i> , 2017, 8, e3065-e3065.	2.7	53
158	Substrate-Dependence of Competitive Nucleotide Pyrophosphatase/Phosphodiesterase1 (NPP1) Inhibitors. <i>Frontiers in Pharmacology</i> , 2017, 8, 54.	1.6	36
159	Interaction of Purinergic P2X <sub>4</sub> and P2X <sub>7</sub> Receptor Subunits. <i>Frontiers in Pharmacology</i> , 2017, 8, 860.	1.6	56
160	Dinosaur origin of egg color: oviraptors laid blue-green eggs. <i>PeerJ</i> , 2017, 5, e3706.	0.9	38
161	Ethanol and Caffeine Effects on Social Interaction and Recognition in Mice: Involvement of Adenosine A <sub>2A</sub> and A <sub>1</sub> Receptors. <i>Frontiers in Behavioral Neuroscience</i> , 2016, 10, 206.	1.0	25
162	Chemical Genetic Analysis and Functional Characterization of Staphylococcal Wall Teichoic Acid 2-Epimerases Reveals Unconventional Antibiotic Drug Targets. <i>PLoS Pathogens</i> , 2016, 12, e1005585.	2.1	35

#	ARTICLE	IF	CITATIONS
163	Antraquinones As Pharmacological Tools and Drugs. <i>Medicinal Research Reviews</i> , 2016, 36, 705-748.	5.0	300
164	Pharmacological evaluation of synthetic cannabinoids identified as constituents of spice. <i>Forensic Toxicology</i> , 2016, 34, 329-343.	1.4	96
165	Focused screening to identify new adenosine kinase inhibitors. <i>Bioorganic and Medicinal Chemistry</i> , 2016, 24, 5127-5133.	1.4	12
166	Inhibitors for the bacterial ectonucleotidase Lp1NTPDase from <i>Legionella pneumophila</i> . <i>Bioorganic and Medicinal Chemistry</i> , 2016, 24, 4363-4371.	1.4	13
167	Effort-related motivational effects of the pro-inflammatory cytokine interleukin-6: pharmacological and neurochemical characterization. <i>Psychopharmacology</i> , 2016, 233, 3575-3586.	1.5	67
168	2-Amino[1,2,4]triazolo[1,5-c]quinazolines and Derived Novel Heterocycles: Syntheses and Structure-Activity Relationships of Potent Adenosine Receptor Antagonists. <i>ChemMedChem</i> , 2016, 11, 2272-2286.	1.6	28
169	Similarities and differences in affinity and binding modes of tricyclic pyrimido- and pyrazinoxanthines at human and rat adenosine receptors. <i>Bioorganic and Medicinal Chemistry</i> , 2016, 24, 4347-4362.	1.4	20
170	8-Substituted 1,3-dimethyltetrahydropyrazino[2,1-f]purinediones: Water-soluble adenosine receptor antagonists and monoamine oxidase B inhibitors. <i>Bioorganic and Medicinal Chemistry</i> , 2016, 24, 5462-5480.	1.4	23
171	Potent Suppressive Effects of 1-Piperidinylimidazole Based Novel P2X7 Receptor Antagonists on Cancer Cell Migration and Invasion. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 7410-7430.	2.9	34
172	G-Protein-Coupled Receptors: Sustained Signaling via Intracellular Megaplexes and Pathway-Specific Drugs. <i>Angewandte Chemie - International Edition</i> , 2016, 55, 15962-15964.	7.2	7
173	Characterization of non-olfactory GPCRs in human sperm with a focus on GPR18. <i>Scientific Reports</i> , 2016, 6, 32255.	1.6	27
174	The caffeine-binding adenosine A2A receptor induces age-like HPA-axis dysfunction by targeting glucocorticoid receptor function. <i>Scientific Reports</i> , 2016, 6, 31493.	1.6	55
175	Thiazolo[3,2-a]benzimidazol-3(2H)-one derivatives: Structure-activity relationships of selective nucleotide pyrophosphatase/phosphodiesterase1 (NPP1) inhibitors. <i>Bioorganic and Medicinal Chemistry</i> , 2016, 24, 3157-3165.	1.4	19
176	Role of extracellular cysteine residues in the adenosine A2A receptor. <i>Purinergic Signalling</i> , 2016, 12, 313-329.	1.1	23
177	Ullmann reactions of 1-amino-4-bromoanthraquinones bearing various 2-substituents furnishing novel dyes. <i>Dyes and Pigments</i> , 2016, 131, 33-40.	2.0	17
178	Medicinal chemistry of adenosine, P2Y and P2X receptors. <i>Neuropharmacology</i> , 2016, 104, 31-49.	2.0	213
179	Induction of oral tremor in mice by the acetylcholinesterase inhibitor galantamine: Reversal with adenosine A2A antagonism. <i>Pharmacology Biochemistry and Behavior</i> , 2016, 140, 62-67.	1.3	7
180	A2A adenosine receptor deletion is protective in a mouse model of Tauopathy. <i>Molecular Psychiatry</i> , 2016, 21, 97-107.	4.1	145

#	ARTICLE	IF	CITATIONS
181	Dual target strategy: combining distinct non-dopaminergic treatments reduces neuronal cell loss and synergistically modulates DOPA-induced rotational behavior in a rodent model of Parkinson's disease. <i>Journal of Neurochemistry</i> , 2015, 134, 740-747.	2.1	31
182	P2Y2 and Gq/G11 control blood pressure by mediating endothelial mechanotransduction. <i>Journal of Clinical Investigation</i> , 2015, 125, 3077-3086.	3.9	145
183	Syntheses of 2-substituted 1-amino-4-bromoanthraquinones (bromaminic acid analogues) – precursors for dyes and drugs. <i>Beilstein Journal of Organic Chemistry</i> , 2015, 11, 2326-2333.	1.3	16
184	Caffeine acts through neuronal adenosine A <sub>2A</sub> receptors to prevent mood and memory dysfunction triggered by chronic stress. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 7833-7838.	3.3	248
185	The experimental power of FR900359 to study Gq-regulated biological processes. <i>Nature Communications</i> , 2015, 6, 10156.	5.8	282
186	The nucleobase adenine as a signalling molecule in the kidney. <i>Acta Physiologica</i> , 2015, 213, 808-818.	1.8	19
187	The VMAT-2 inhibitor tetrabenazine alters effort-related decision making as measured by the T-maze barrier choice task: reversal with the adenosine A <sub>2A</sub> antagonist MSX-3 and the catecholamine uptake blocker bupropion. <i>Psychopharmacology</i> , 2015, 232, 1313-1323.	1.5	84
188	Shear stress modulates endothelial KLF2 through activation of P2X4. <i>Purinergic Signalling</i> , 2015, 11, 139-153.	1.1	41
189	A capillary electrophoresis method with dynamic pH junction stacking for the monitoring of cerebroside sulfotransferase. <i>Journal of Chromatography A</i> , 2015, 1407, 222-227.	1.8	7
190	1,2-Methylene-ADP (AOPCP) Derivatives and Analogues: Development of Potent and Selective 5'-Nucleotidase (CD73) Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2015, 58, 6248-6263.	2.9	110
191	Selectivity is species-dependent: Characterization of standard agonists and antagonists at human, rat, and mouse adenosine receptors. <i>Purinergic Signalling</i> , 2015, 11, 389-407.	1.1	111
192	Modeling ligand recognition at the P2Y <sub>12</sub> receptor in light of X-ray structural information. <i>Journal of Computer-Aided Molecular Design</i> , 2015, 29, 737-756.	1.3	42
193	Inactivation of adenosine A <sub>2A</sub> receptors reverses working memory deficits at early stages of Huntington's disease models. <i>Neurobiology of Disease</i> , 2015, 79, 70-80.	2.1	83
194	Fluorescence polarization immunoassays for monitoring nucleoside triphosphate diphosphohydrolase (NTPDase) activity. <i>Analyst, The</i> , 2015, 140, 140-148.	1.7	16
195	P2Y <sub>12</sub> Receptor Localizes in the Renal Collecting Duct and Its Blockade Augments Arginine Vasopressin Action and Alleviates Nephrogenic Diabetes Insipidus. <i>Journal of the American Society of Nephrology: JASN</i> , 2015, 26, 2978-2987.	3.0	49
196	GPR18 Inhibiting Amauromine and the Novel Triterpene Glycoside Auxarthonoside from the Sponge-Derived Fungus <i>Auxarthon reticulatum</i> . <i>Planta Medica</i> , 2015, 81, 1141-1145.	0.7	18
197	Targeting renal purinergic signalling for the treatment of lithium-induced nephrogenic diabetes insipidus. <i>Acta Physiologica</i> , 2015, 214, 176-188.	1.8	28
198	Adenosine A <sub>2A</sub> Receptor Antagonists in Drug Development. <i>Current Topics in Neurotoxicity</i> , 2015, , 39-56.	0.4	1

#	ARTICLE	IF	CITATIONS
199	Clopidogrel attenuates lithium-induced alterations in renal water and sodium channels/transporters in mice. <i>Purinergic Signalling</i> , 2015, 11, 507-518.	1.1	17
200	Polyoxometalates – Potent and selective ecto-nucleotidase inhibitors. <i>Biochemical Pharmacology</i> , 2015, 93, 171-181.	2.0	107
201	Medicinal Chemistry of P2X Receptors: Allosteric Modulators. <i>Current Medicinal Chemistry</i> , 2015, 22, 929-941.	1.2	37
202	Large-volume sample stacking with polarity switching for monitoring of nucleotide pyrophosphatase/phosphodiesterase 1 (NPP1) reactions by capillary electrophoresis. <i>Electrophoresis</i> , 2014, 35, 855-863.	1.3	21
203	Structural analogues of the natural products magnolol and honokiol as potent allosteric potentiators of GABAA receptors. <i>Bioorganic and Medicinal Chemistry</i> , 2014, 22, 6908-6917.	1.4	23
204	Competitive mode and site of interaction of ticagrelor at the human platelet P2Y <sub>12</sub> receptor. <i>Journal of Thrombosis and Haemostasis</i> , 2014, 12, 1898-1905.	1.9	47
205	Bispidines for Dual Imaging. <i>Chemistry - A European Journal</i> , 2014, 20, 17011-17018.	1.7	31
206	Neuroprotective Potential of Adenosine A <sub>2A</sub> and Cannabinoid CB <sub>1</sub> Receptor Antagonists in an Animal Model of Parkinson Disease. <i>Journal of Neuro pathology and Experimental Neurology</i> , 2014, 73, 414-424.	0.9	31
207	Carbamazepine derivatives with P2X <sub>4</sub> receptor-blocking activity. <i>Bioorganic and Medicinal Chemistry</i> , 2014, 22, 1077-1088.	1.4	37
208	A new, sensitive ecto-5'-nucleotidase assay for compound screening. <i>Analytical Biochemistry</i> , 2014, 446, 53-58.	1.1	40
209	L-DOPA-treatment in primates disrupts the expression of A <sub>2A</sub> adenosine – CB <sub>1</sub> cannabinoid – D <sub>2</sub> dopamine receptor heteromers in the caudate nucleus. <i>Neuropharmacology</i> , 2014, 79, 90-100.	2.0	83
210	Impact of in vivo chronic blockade of adenosine A <sub>2A</sub> receptors on the BDNF-mediated facilitation of LTP. <i>Neuropharmacology</i> , 2014, 83, 99-106.	2.0	31
211	Beneficial effects of caffeine in a transgenic model of Alzheimer's disease-like tau pathology. <i>Neurobiology of Aging</i> , 2014, 35, 2079-2090.	1.5	163
212	Synthesis of BODIPY Derivatives Substituted with Various Bioconjugatable Linker Groups: A Construction Kit for Fluorescent Labeling of Receptor Ligands. <i>Journal of Fluorescence</i> , 2014, 24, 213-230.	1.3	27
213	Effort-related motivational effects of the pro-inflammatory cytokine interleukin 1-beta: studies with the concurrent fixed ratio 5/ chow feeding choice task. <i>Psychopharmacology</i> , 2014, 231, 727-736.	1.5	91
214	Structure of the human P2Y <sub>12</sub> receptor in complex with an antithrombotic drug. <i>Nature</i> , 2014, 509, 115-118.	18.7	330
215	BAY60-6583 Acts as a Partial Agonist at Adenosine A <sub>2B</sub> Receptors. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2014, 349, 427-436.	1.3	49
216	Bicyclic imidazole-4-one derivatives: a new class of antagonists for the orphan G protein-coupled receptors GPR18 and GPR55. <i>MedChemComm</i> , 2014, 5, 632-649.	3.5	24

#	ARTICLE	IF	CITATIONS
217	Improved synthesis of 4-/6-substituted 2-carboxy-1H-indole-3-propionic acid derivatives and structure-activity relationships as GPR17 agonists. <i>MedChemComm</i> , 2014, 5, 86-92.	3.5	11
218	Imidazopyridine- and Purine-Thioacetamide Derivatives: Potent Inhibitors of Nucleotide Pyrophosphatase/Phosphodiesterase 1 (NPP1). <i>Journal of Medicinal Chemistry</i> , 2014, 57, 10080-10100.	2.9	62
219	8-Benzyltetrahydropyrazino[2,1-f]purinediones: Water-Soluble Tricyclic Xanthine Derivatives as Multitarget Drugs for Neurodegenerative Diseases. <i>ChemMedChem</i> , 2014, 9, 1704-1724.	1.6	23
220	Central P2Y12 receptor blockade alleviates inflammatory and neuropathic pain and cytokine production in rodents. <i>Neurobiology of Disease</i> , 2014, 70, 162-178.	2.1	77
221	Adenosine activates brown adipose tissue and recruits beige adipocytes via A2A receptors. <i>Nature</i> , 2014, 516, 395-399.	13.7	316
222	Indoloditerpenes from a Marine-Derived Fungal Strain of <i>Dichotomomyces cejpai</i> with Antagonistic Activity at GPR18 and Cannabinoid Receptors. <i>Journal of Natural Products</i> , 2014, 77, 673-677.	1.5	38
223	Characterization of circulating microparticle-associated CD39 family ecto-nucleotidases in human plasma. <i>Purinergic Signalling</i> , 2014, 10, 611-618.	1.1	27
224	Domains for activation and inactivation in G protein-coupled receptors - A mutational analysis of constitutive activity of the adenosine A2B receptor. <i>Biochemical Pharmacology</i> , 2014, 92, 348-357.	2.0	9
225	Indazole- and Indole-5-carboxamides: Selective and Reversible Monoamine Oxidase B Inhibitors with Subnanomolar Potency. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 6679-6703.	2.9	77
226	Crystal structure of NTPDase2 in complex with the sulfoanthraquinone inhibitor PSB-071. <i>Journal of Structural Biology</i> , 2014, 185, 336-341.	1.3	25
227	A novel receptor cross-talk between the ATP receptor P2Y2 and formyl peptide receptors reactivates desensitized neutrophils to produce superoxide. <i>Experimental Cell Research</i> , 2014, 323, 209-217.	1.2	46
228	Alkynyl-coumarinyl ethers as MAO-B inhibitors. <i>Bioorganic and Medicinal Chemistry</i> , 2014, 22, 1916-1928.	1.4	40
229	l-DOPA disrupts adenosine A2A-cannabinoid CB1-dopamine D2 receptor heteromer cross-talk in the striatum of hemiparkinsonian rats: Biochemical and behavioral studies. <i>Experimental Neurology</i> , 2014, 253, 180-191.	2.0	77
230	Development of [ <sup>3</sup> H]-2-Carboxy-4,6-dichloro-1H-indole-3-propionic Acid ([ <sup>3</sup> H]PSB-12150): A Useful Tool for Studying GPR17. <i>ACS Medicinal Chemistry Letters</i> , 2014, 5, 326-330.	1.3	16
231	Agonist-bound structure of the human P2Y12 receptor. <i>Nature</i> , 2014, 509, 119-122.	13.7	279
232	Analysis of the <i>Staphylococcus aureus</i> capsule biosynthesis pathway in vitro: Characterization of the UDP-GlcNAc C6 dehydratases CapD and CapE and identification of enzyme inhibitors. <i>International Journal of Medical Microbiology</i> , 2014, 304, 958-969.	1.5	22
233	Cardiac myocyte-secreted cAMP exerts paracrine action via adenosine receptor activation. <i>Journal of Clinical Investigation</i> , 2014, 124, 5385-5397.	3.9	70
234	The VMAT-2 Inhibitor Tetrabenazine Affects Effort-Related Decision Making in a Progressive Ratio/Chow Feeding Choice Task: Reversal with Antidepressant Drugs. <i>PLoS ONE</i> , 2014, 9, e99320.	1.1	82

#	ARTICLE	IF	CITATIONS
235	Synthesis, biological activity and molecular modelling studies of tricyclic alkylimidazo-, pyrimido- and diazopinopurinediones. <i>Purinergic Signalling</i> , 2013, 9, 395-414.	1.1	16
236	Deep brain stimulation of the subthalamic nucleus reverses oral tremor in pharmacological models of parkinsonism: interaction with the effects of adenosine A <sub>2A</sub> antagonism. <i>European Journal of Neuroscience</i> , 2013, 38, 2183-2191.	1.2	18
237	P2Y2 receptor agonist with enhanced stability protects the heart from ischemic damage in vitro and in vivo. <i>Purinergic Signalling</i> , 2013, 9, 633-642.	1.1	34
238	Characterization of new G protein-coupled adenine receptors in mouse and hamster. <i>Purinergic Signalling</i> , 2013, 9, 415-426.	1.1	31
239	The rat adenine receptor: pharmacological characterization and mutagenesis studies to investigate its putative ligand binding site. <i>Purinergic Signalling</i> , 2013, 9, 367-381.	1.1	16
240	Antiproliferative effects of selective adenosine receptor agonists and antagonists on human lymphocytes: evidence for receptor-independent mechanisms. <i>Purinergic Signalling</i> , 2013, 9, 351-365.	1.1	32
241	6-Bromo-8-(4-( <sup>3</sup> H)methoxybenzamido)-4-oxo-4 <i>H</i> -chromene-2-carboxylic Acid: A Powerful Tool for Studying Orphan G Protein-Coupled Receptor GPR35. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 7084-7099.	2.9	33
242	1,3-Dialkyl-substituted tetrahydropyrimido[1,2-f]purine-2,4-diones as multiple target drugs for the potential treatment of neurodegenerative diseases. <i>Bioorganic and Medicinal Chemistry</i> , 2013, 21, 7435-7452.	1.4	29
243	Ecto-5'-Nucleotidase (CD73)-Mediated Formation of Adenosine Is Critical for the Striatal Adenosine A <sub>2A</sub> Receptor Functions. <i>Journal of Neuroscience</i> , 2013, 33, 11390-11399.	1.7	146
244	Advances in immobilized enzyme microreactors in capillary electrophoresis. <i>Analyst</i> , The, 2013, 138, 3104.	1.7	77
245	Ligand-Specific Binding and Activation of the Human Adenosine A <sub>2B</sub> Receptor. <i>Biochemistry</i> , 2013, 52, 726-740.	1.2	38
246	Magnolia Extract, Magnolol, and Metabolites: Activation of Cannabinoid CB <sub>2</sub> Receptors and Blockade of the Related GPR55. <i>ACS Medicinal Chemistry Letters</i> , 2013, 4, 41-45.	1.3	74
247	The vesicular monoamine transporter (VMAT-2) inhibitor tetrabenazine induces tremulous jaw movements in rodents: Implications for pharmacological models of parkinsonian tremor. <i>Neuroscience</i> , 2013, 250, 507-519.	1.1	21
248	Effect of subtype-selective adenosine receptor antagonists on basal or haloperidol-regulated striatal function: Studies of exploratory locomotion and c-Fos immunoreactivity in outbred and A <sub>2A</sub> KO mice. <i>Behavioural Brain Research</i> , 2013, 247, 217-226.	1.2	31
249	Conditional neural knockout of the adenosine A <sub>2A</sub> receptor and pharmacological A <sub>2A</sub> antagonism reduce pilocarpine-induced tremulous jaw movements: Studies with a mouse model of parkinsonian tremor. <i>European Neuropsychopharmacology</i> , 2013, 23, 972-977.	0.3	25
250	The second extracellular loop of GPCRs determines subtype-selectivity and controls efficacy as evidenced by loop exchange study at A <sub>2</sub> adenosine receptors. <i>Biochemical Pharmacology</i> , 2013, 85, 1317-1329.	2.0	34
251	The platelet P2Y <sub>12</sub> receptor under normal and pathological conditions. Assessment with the radiolabeled selective antagonist [ <sup>3</sup> H]PSB-0413. <i>Purinergic Signalling</i> , 2013, 9, 59-66.	1.1	38
252	Adenosine A <sub>2A</sub> receptor blockade reverts hippocampal stress-induced deficits and restores corticosterone circadian oscillation. <i>Molecular Psychiatry</i> , 2013, 18, 320-331.	4.1	124

#	ARTICLE	IF	CITATIONS
253	Polyoxometalates as Versatile Enzyme Inhibitors. <i>European Journal of Inorganic Chemistry</i> , 2013, 2013, 1585-1594.	1.0	132
254	8-Benzamidochromen-4-one-2-carboxylic Acids: Potent and Selective Agonists for the Orphan G Protein-Coupled Receptor GPR35. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 5182-5197.	2.9	37
255	Antagonists for the Orphan G-Protein-Coupled Receptor GPR55 Based on a Coumarin Scaffold. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 4798-4810.	2.9	50
256	Dual Targeting of Adenosine A <sub>2A</sub> Receptors and Monoamine Oxidase B by 4 <i>H</i> -3,1-Benzothiazin-4-ones. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 4580-4596.	2.9	78
257	Synthesis of Novel Pyrido[3,2- <i>h</i> ][1,2,4]triazolo[1,5- <i>c</i> ]pyrimidine Derivatives: Potent and Selective Adenosine A <sub>3</sub> Receptor Antagonists. <i>Archiv Der Pharmazie</i> , 2013, 346, 699-707.	2.1	10
258	Cellular localization of adenosine receptors in the rat kidney and their functional significance in the inner medullary collecting duct. <i>American Journal of Physiology - Renal Physiology</i> , 2013, 305, F1298-F1305.	1.3	12
259	Effort-Related Motivational Effects of the VMAT-2 Inhibitor Tetrabenazine: Implications for Animal Models of the Motivational Symptoms of Depression. <i>Journal of Neuroscience</i> , 2013, 33, 19120-19130.	1.7	114
260	Decoding Signaling and Function of the Orphan G Protein-Coupled Receptor GPR17 with a Small-Molecule Agonist. <i>Science Signaling</i> , 2013, 6, ra93.	1.6	111
261	Adenosine Receptor Antagonists Including Caffeine Alter Fetal Brain Development in Mice. <i>Science Translational Medicine</i> , 2013, 5, 197ra104.	5.8	148
262	The Natural Product Magnolol as a Lead Structure for the Development of Potent Cannabinoid Receptor Agonists. <i>PLoS ONE</i> , 2013, 8, e77739.	1.1	32
263	Convergent Synthesis of the Potent P2Y Receptor Antagonist MG 50-3-1 Based on a Regioselective Ullmann Coupling Reaction. <i>Molecules</i> , 2012, 17, 2599-2615.	1.7	19
264	Crystal Structure of the Human Ecto-5'-Nucleotidase (CD73): Insights into the Regulation of Purinergic Signaling. <i>Structure</i> , 2012, 20, 2161-2173.	1.6	164
265	Efficient and mild deamination procedure for 1-aminoanthraquinones yielding a diverse library of novel derivatives with potential biological activity. <i>Tetrahedron Letters</i> , 2012, 53, 6739-6742.	0.7	18
266	Facile synthesis of 5-amino- and 7-amino-6-azaoxindole derivatives. <i>Tetrahedron Letters</i> , 2012, 53, 5597-5601.	0.7	5
267	Enantiomerically enriched trans-diols from alkenes in one pot: a multicatalyst approach. <i>Chemical Communications</i> , 2012, 48, 2498.	2.2	27
268	Adenosine A <sub>2A</sub> receptor antagonism and genetic deletion attenuate the effects of dopamine D <sub>2</sub> antagonism on effort-based decision making in mice. <i>Neuropharmacology</i> , 2012, 62, 2068-2077.	2.0	108
269	The novel adenosine A <sub>2A</sub> antagonist prodrug MSX-4 is effective in animal models related to motivational and motor functions. <i>Pharmacology Biochemistry and Behavior</i> , 2012, 102, 477-487.	1.3	44
270	Allosteric modulators of rhodopsin-like G protein-coupled receptors: Opportunities in drug development. , 2012, 135, 292-315.		62



#	ARTICLE	IF	CITATIONS
271	Selective Activation of Adenosine A <sub>2A</sub> Receptors on Immune Cells by a CD73-Dependent Prodrug Suppresses Joint Inflammation in Experimental Rheumatoid Arthritis. <i>Science Translational Medicine</i> , 2012, 4, 146ra108.	5.8	111
272	7-Alkyl-3-benzylcoumarins: A Versatile Scaffold for the Development of Potent and Selective Cannabinoid Receptor Agonists and Antagonists. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 7967-7977.	2.9	34
273	N-Substituted Phenoxazine and Acridone Derivatives: Structure-Activity Relationships of Potent P2X4 Receptor Antagonists. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 9576-9588.	2.9	100
274	A highly sensitive capillary electrophoresis method using p-nitrophenyl 5'-thymidine monophosphate as a substrate for the monitoring of nucleotide pyrophosphatase/phosphodiesterase activities. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2012, 911, 162-169.	1.2	18
275	Benzothiazinones: A Novel Class of Adenosine Receptor Antagonists Structurally Unrelated to Xanthine and Adenine Derivatives. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 3331-3341.	2.9	52
276	Virtual Screening Identifies Novel Sulfonamide Inhibitors of Ecto-5'-Nucleotidase. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 6576-6581.	2.9	47
277	Regioselective synthesis of 7,8-dihydroimidazo[5,1-c][1,2,4]triazine-3,6(2H,4H)-dione derivatives: A new drug-like heterocyclic scaffold. <i>Beilstein Journal of Organic Chemistry</i> , 2012, 8, 1584-1593.	1.3	13
278	Farnesyl pyrophosphate is an endogenous antagonist to ADP-stimulated P2Y12 receptor-mediated platelet aggregation. <i>Thrombosis and Haemostasis</i> , 2012, 108, 119-132.	1.8	10
279	Tritium-Labeled Brivaracetam with High Specific Activity: Preparation, Characterization and Application in Human Brain Samples. <i>ChemMedChem</i> , 2012, 7, 1369-1374.	1.6	7
280	Adenosine A2A receptor contributes to the anti-inflammatory effect of the fixed herbal combination STW 5 (Iberogast®) in rat small intestinal preparations. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2012, 385, 411-421.	1.4	10
281	Ecto-ATPase inhibition: ATP and adenosine release under physiological and ischemic in vivo conditions in the rat striatum. <i>Experimental Neurology</i> , 2012, 233, 193-204.	2.0	84
282	Synthesis of tritium-labeled levetiracetam ((S)-2-(oxopyrrolidin-1-yl)butanamide) with high specific activity. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2012, 55, 48-51.	0.5	4
283	International Conference on Purinergic Drugs and Targets 4th Joint German-Italian Purine Club Meeting, Bonn, Germany, July 22-25, 2011. <i>Purinergic Signalling</i> , 2012, 8, 105-106.	1.1	2
284	Dopaminergic Modulation of Effort-Related Choice Behavior as Assessed by a Progressive Ratio Chow Feeding Choice Task: Pharmacological Studies and the Role of Individual Differences. <i>PLoS ONE</i> , 2012, 7, e47934.	1.1	166
285	Cellular Localization of P0 (Adenine) Receptor in Rat Kidney. <i>FASEB Journal</i> , 2012, 26, 688.3.	0.2	3
286	Development of Polar Adenosine A <sub>2A</sub> Receptor Agonists for Inflammatory Bowel Disease: Synergism with A <sub>2B</sub> Antagonists. <i>ACS Medicinal Chemistry Letters</i> , 2011, 2, 890-895.	1.3	40
287	International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and Classification of Adenosine Receptors: An Update. <i>Pharmacological Reviews</i> , 2011, 63, 1-34.	7.1	1,135
288	Identification of a Potent and Selective Cannabinoid CB <sub>1</sub> Receptor Antagonist from <i>Auxarthron reticulatum</i> . <i>ACS Medicinal Chemistry Letters</i> , 2011, 2, 866-869.	1.3	56

#	ARTICLE	IF	CITATIONS
289	A Combined Experimental and Simulation Approach to Develop Selective High-Affinity Small-Molecule Inhibitors of Cannabinoid Receptors CB1/CB2. <i>Biophysical Journal</i> , 2011, 100, 548a-549a.	0.2	0
290	Structural Modifications of UMP, UDP, and UTP Leading to Subtype-Selective Agonists for P2Y <sub>2</sub> , P2Y <sub>4</sub> , and P2Y <sub>6</sub> Receptors. <i>Journal of Medicinal Chemistry</i> , 2011, 54, 2878-2890.	2.9	45
291	Xanthines as Adenosine Receptor Antagonists. <i>Handbook of Experimental Pharmacology</i> , 2011, , 151-199.	0.9	107
292	Recent developments in adenosine receptor ligands and their potential as novel drugs. <i>Biochimica Et Biophysica Acta - Biomembranes</i> , 2011, 1808, 1290-1308.	1.4	375
293	Discovery of Potent Competitive Antagonists and Positive Modulators of the P2X2 Receptor. <i>Journal of Medicinal Chemistry</i> , 2011, 54, 817-830.	2.9	63
294	Reinforcing and neurochemical effects of cannabinoid CB1 receptor agonists, but not cocaine, are altered by an adenosine A2A receptor antagonist. <i>Addiction Biology</i> , 2011, 16, 405-415.	1.4	50
295	Oral tremor induced by galantamine in rats: A model of the parkinsonian side effects of cholinomimetics used to treat Alzheimer's disease. <i>Pharmacology Biochemistry and Behavior</i> , 2011, 99, 414-422.	1.3	31
296	Past, present and future of A2A adenosine receptor antagonists in the therapy of Parkinson's disease. , 2011, 132, 280-299.		170
297	Synthesis and biological activity of tricyclic cycloalkylimidazo-, pyrimido- and diazepinopurinediones. <i>European Journal of Medicinal Chemistry</i> , 2011, 46, 3590-3607.	2.6	32
298	The four cysteine residues in the second extracellular loop of the human adenosine A2B receptor: Role in ligand binding and receptor function. <i>Biochemical Pharmacology</i> , 2011, 82, 389-399.	2.0	35
299	Effect of the adenosine A2A receptor antagonist MSX-3 on motivational disruptions of maternal behavior induced by dopamine antagonism in the early postpartum rat. <i>Psychopharmacology</i> , 2011, 213, 69-79.	1.5	30
300	Stimulant effects of adenosine antagonists on operant behavior: differential actions of selective A2A and A1 antagonists. <i>Psychopharmacology</i> , 2011, 216, 173-186.	1.5	44
301	Antiparkinsonian Effects of Novel Adenosine A <sub>2A</sub> Receptor Antagonists. <i>Archiv Der Pharmazie</i> , 2011, 344, 20-27.	2.1	14
302	High-sensitivity capillary electrophoresis method for monitoring purine nucleoside phosphorylase and adenosine deaminase reactions by a reversed electrode polarity switching mode. <i>Journal of Chromatography A</i> , 2011, 1218, 4764-4771.	1.8	26
303	Structure-activity relationships of flavonoids as inhibitors of breast cancer resistance protein (BCRP). <i>Bioorganic and Medicinal Chemistry</i> , 2011, 19, 2090-2102.	1.4	169
304	GPCR structure and activation: an essential role for the first extracellular loop in activating the adenosine A <sub>2B</sub> receptor. <i>FASEB Journal</i> , 2011, 25, 632-643.	0.2	44
305	Crystal structure of 6-amino-3-cyclopropyl-1-ethyl-1Hpyrimidine- 2,4-dione hydrate, C <sub>9</sub> H <sub>13</sub> N <sub>3</sub> O <sub>2</sub> · H <sub>2</sub> O. <i>Zeitschrift Fur Kristallographie - New Crystal Structures</i> , 2010, 225, 595-596.	0.1	0
306	Adenosine A2A agonist and A2B antagonist mediate an inhibition of inflammation-induced contractile disturbance of a rat gastrointestinal preparation. <i>Purinergic Signalling</i> , 2010, 6, 117-124.	1.1	22

#	ARTICLE	IF	CITATIONS
307	Emerging structures and ligands for P2X3 and P2X4 receptors towards novel treatments of neuropathic pain. <i>Purinergic Signalling</i> , 2010, 6, 145-148.	1.1	18
308	Chronic A2A antagonist treatment alleviates parkinsonian locomotor deficiency in MitoPark mice. <i>Neurobiology of Disease</i> , 2010, 40, 460-466.	2.1	25
309	Oral tremor induced by the muscarinic agonist pilocarpine is suppressed by the adenosine A2A antagonists MSX-3 and SCH58261, but not the adenosine A1 antagonist DPCPX. <i>Pharmacology Biochemistry and Behavior</i> , 2010, 94, 561-569.	1.3	41
310	Development of a microbioreactor with ecto-nucleoside triphosphate diphosphohydrolase 2 (NTPDase2) immobilized on a polyacrylamide-coated capillary at the outlet. <i>Journal of Chromatography A</i> , 2010, 1217, 600-604.	1.8	12
311	2-Amino-5-benzoyl-4-phenylthiazoles: Development of potent and selective adenosine A1 receptor antagonists. <i>Bioorganic and Medicinal Chemistry</i> , 2010, 18, 2195-2203.	1.4	29
312	2-Phenyl-1-[4-(2-piperidine-1-yl-ethoxy)benzyl]-1H-benzimidazoles as ligands for the estrogen receptor: Synthesis and pharmacological evaluation. <i>Bioorganic and Medicinal Chemistry</i> , 2010, 18, 4905-4916.	1.4	15
313	Synthesis of a hydrolytically stable, fluorescent-labeled ATP analog as a tool for probing adenyl cyclases. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2010, 20, 232-235.	1.0	3
314	Caffeine and an adenosine A <sub>2A</sub> receptor antagonist prevent memory impairment and synaptotoxicity in adult rats triggered by a convulsive episode in early life. <i>Journal of Neurochemistry</i> , 2010, 112, 453-462.	2.1	115
315	Synthesis of alkyl- and aryl-amino-substituted anthraquinone derivatives by microwave-assisted copper(0)-catalyzed Ullmann coupling reactions. <i>Nature Protocols</i> , 2010, 5, 945-953.	5.5	52
316	CD39/ENTPD1 Expression by CD4 <sup>+</sup> Foxp3 <sup>+</sup> Regulatory T Cells Promotes Hepatic Metastatic Tumor Growth in Mice. <i>Gastroenterology</i> , 2010, 139, 1030-1040.	0.6	240
317	Interactions between adenosine and dopamine receptor antagonists with different selectivity profiles: Effects on locomotor activity. <i>Behavioural Brain Research</i> , 2010, 211, 148-155.	1.2	45
318	Nucleus accumbens and effort-related functions: behavioral and neural markers of the interactions between adenosine A2A and dopamine D2 receptors. <i>Neuroscience</i> , 2010, 166, 1056-1067.	1.1	103
319	Development of Potent and Selective Inhibitors of ecto-5'-Nucleotidase Based on an Anthraquinone Scaffold. <i>Journal of Medicinal Chemistry</i> , 2010, 53, 2076-2086.	2.9	88
320	Blocking Striatal Adenosine A2A Receptors: A New Strategy for Basal Ganglia Disorders. , 2010, , 304-341.		4
321	Interaction of New, Very Potent Non-Nucleotide Antagonists with Arg256 of the Human Platelet P2Y <sub>12</sub> Receptor. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2009, 331, 648-655.	1.3	59
322	Crystal structure of 3-benzyl-5,5-dimethylimidazolidine-2,4-dione, C <sub>12</sub> H <sub>14</sub> N <sub>2</sub> O <sub>2</sub> . <i>Zeitschrift Fur Kristallographie - New Crystal Structures</i> , 2009, 224, 601-602.	0.1	1
323	Extracellular NAD <sup>+</sup> induces a rise in [Ca <sup>2+</sup> ] <sub>i</sub> in activated human monocytes via engagement of P2Y1 and P2Y11 receptors. <i>Cell Calcium</i> , 2009, 46, 263-272.	1.1	49
324	Preparation of enantiopure (R)-hydroxy metabolite of denbufylline using immobilized <i>Lactobacillus kefir</i> DSM 20587 as a catalyst. <i>Chirality</i> , 2009, 21, 713-718.	1.3	3

#	ARTICLE	IF	CITATIONS
325	Prodrug Approaches for Enhancing the Bioavailability of Drugs with Low Solubility. <i>Chemistry and Biodiversity</i> , 2009, 6, 2071-2083.	1.0	110
326	Homology modelling of the human adenosine A2B receptor based on X-ray structures of bovine rhodopsin, the $\beta_2$ -adrenergic receptor and the human adenosine A2A receptor. <i>Journal of Computer-Aided Molecular Design</i> , 2009, 23, 807-28.	1.3	38
327	Structure-activity relationships of anthraquinone derivatives derived from bromaminic acid as inhibitors of ectonucleoside triphosphate diphosphohydrolases (E-NTPDases). <i>Purinergic Signalling</i> , 2009, 5, 91-106.	1.1	64
328	The adenosine A2A antagonist MSX-3 reverses the effort-related effects of dopamine blockade: differential interaction with D1 and D2 family antagonists. <i>Psychopharmacology</i> , 2009, 203, 489-499.	1.5	66
329	The adenosine A2A antagonist MSX-3 reverses the effects of the dopamine antagonist haloperidol on effort-related decision making in a T-maze cost/benefit procedure. <i>Psychopharmacology</i> , 2009, 204, 103-112.	1.5	105
330	Adenosine regulates CD8 T cell priming by inhibition of membrane proximal T cell receptor signalling. <i>Immunology</i> , 2009, 128, e728-37.	2.0	94
331	Synthesis and pharmacological evaluation of coumarin derivatives as cannabinoid receptor antagonists and inverse agonists. <i>Bioorganic and Medicinal Chemistry</i> , 2009, 17, 2842-2851.	1.4	53
332	Synthesis of uracil nucleotide analogs with a modified, acyclic ribose moiety as P2Y2 receptor antagonists. <i>Bioorganic and Medicinal Chemistry</i> , 2009, 17, 5071-5079.	1.4	28
333	Structure-Activity Relationships of Adenine and Deazaadenine Derivatives as Ligands for Adenine Receptors, a New Purinergic Receptor Family. <i>Journal of Medicinal Chemistry</i> , 2009, 52, 5974-5989.	2.9	43
334	Key Determinants of Nucleotide-Activated G Protein-Coupled P2Y <sub>2</sub> Receptor Function Revealed by Chemical and Pharmacological Experiments, Mutagenesis and Homology Modeling. <i>Journal of Medicinal Chemistry</i> , 2009, 52, 2762-2775.	2.9	73
335	Nucleoside-5'-monophosphates as Prodrugs of Adenosine A <sub>2A</sub> Receptor Agonists Activated by ecto-5'-Nucleotidase: Contribution to celebrate the 100th anniversary of the Division of Medicinal Chemistry of the American Chemical Society. <i>Journal of Medicinal Chemistry</i> , 2009, 52, 7669-7677.	2.9	63
336	Recent Developments in Adenosine A2A Receptor Ligands. <i>Handbook of Experimental Pharmacology</i> , 2009, , 59-98.	0.9	48
337	1-Alkyl-8-(piperazine-1-sulfonyl)phenylxanthines: Development and Characterization of Adenosine A <sub>2B</sub> Receptor Antagonists and a New Radioligand with Subnanomolar Affinity and Subtype Specificity. <i>Journal of Medicinal Chemistry</i> , 2009, 52, 3994-4006.	2.9	143
338	High-Affinity, Non-Nucleotide-Derived Competitive Antagonists of Platelet P2Y <sub>12</sub> Receptors. <i>Journal of Medicinal Chemistry</i> , 2009, 52, 3784-3793.	2.9	89
339	5,5'-Bipyridyl-2,4,6,4',6'-hexaone Derivatives (Hydrylic Acids): Syntheses, Mechanism of C-C-Bond Formation and Properties of the Dimeric Barbituric Acid Derivatives. <i>Heterocycles</i> , 2009, 79, 703.	0.4	2
340	Crystal structure of 1-((2R,3R,4S,5R)-3,4-dihydroxy-5-hydroxymethyltetrahydrofuran-)-Tj ETQq0 0 0 rGBT /Overlock 10 Tf 50 147 Td (2-yl) Structures, 2009, 224, 107-108.	0.1	1
341	Adenosine receptor subtype-selective antagonists in inflammation and hyperalgesia. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2008, 377, 65-76.	1.4	50
342	A highly sensitive CEUV method with dynamic coating of silica fused capillaries for monitoring of nucleotide pyrophosphatase/phosphodiesterase reactions. <i>Electrophoresis</i> , 2008, 29, 3685-3693.	1.3	67

#	ARTICLE	IF	CITATIONS
343	Adenosine A <sub>2A</sub> receptor antagonists exert motor and neuroprotective effects by distinct cellular mechanisms. <i>Annals of Neurology</i> , 2008, 63, 338-346.	2.8	159
344	Capillary electrophoresis-based nanoscale assays for monitoring ecto-5'-nucleotidase activity and inhibition in preparations of recombinant enzyme and melanoma cell membranes. <i>Analytical Biochemistry</i> , 2008, 373, 129-140.	1.1	43
345	Combinatorial synthesis of anilinoanthraquinone derivatives and evaluation as non-nucleotide-derived P2Y <sub>2</sub> receptor antagonists. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2008, 18, 223-227.	1.0	62
346	Ammonium-induced calcium mobilization in 1321N1 astrocytoma cells. <i>Toxicology and Applied Pharmacology</i> , 2008, 227, 36-47.	1.3	13
347	Selective Nucleoside Triphosphate Diphosphohydrolase-2 (NTPDase2) Inhibitors: Nucleotide Mimetics Derived from Uridine-5'-carboxamide. <i>Journal of Medicinal Chemistry</i> , 2008, 51, 4518-4528.	2.9	43
348	Antagonistic cannabinoid CB1/dopamine D2 receptor interactions in striatal CB1/D2 heteromers. A combined neurochemical and behavioral analysis. <i>Neuropharmacology</i> , 2008, 54, 815-823.	2.0	154
349	Dopamine/adenosine interactions related to locomotion and tremor in animal models: Possible relevance to parkinsonism. <i>Parkinsonism and Related Disorders</i> , 2008, 14, S130-S134.	1.1	57
350	Adenosine A <sub>2A</sub> receptor blockade prevents memory dysfunction caused by $\beta$ -amyloid peptides but not by scopolamine or MK-801. <i>Experimental Neurology</i> , 2008, 210, 776-781.	2.0	97
351	Enzymatic Properties of an Ecto-nucleoside Triphosphate Diphosphohydrolase from <i>Legionella pneumophila</i> . <i>Journal of Biological Chemistry</i> , 2008, 283, 12909-12918.	1.6	54
352	Cloning and Functional Expression of a Novel G <sub>i</sub> Protein-Coupled Receptor for Adenine from Mouse Brain. <i>Molecular Pharmacology</i> , 2008, 73, 469-477.	1.0	31
353	Synthesis and Properties of a New Water-Soluble Prodrug of the Adenosine A <sub>2A</sub> Receptor Antagonist MSX-2. <i>Molecules</i> , 2008, 13, 348-359.	1.7	35
354	Tremolytic effects of adenosine A <sub>2A</sub> antagonists: implications for parkinsonism. <i>Frontiers in Bioscience - Landmark</i> , 2008, Volume, 3594.	3.0	74
355	Contribution of Ecto-NTPDase1 (CD39) to renal protection from ischemia-reperfusion injury. <i>FASEB Journal</i> , 2007, 21, 2863-2873.	0.2	140
356	CD39/Ectonucleoside Triphosphate Diphosphohydrolase 1 Provides Myocardial Protection During Cardiac Ischemia/Reperfusion Injury. <i>Circulation</i> , 2007, 116, 1784-1794.	1.6	192
357	The map kinase ERK regulates renal activity of cyclin-dependent kinase 2 in experimental glomerulonephritis. <i>Nephrology Dialysis Transplantation</i> , 2007, 22, 3431-3441.	0.4	11
358	Blocking Striatal Adenosine A <sub>2A</sub> Receptors: A New Strategy for Basal Ganglia Disorders. <i>Recent Patents on CNS Drug Discovery</i> , 2007, 2, 1-21.	0.9	79
359	The Reactivity of Related 6-Amino- and 5,6-Diaminouracils Derived from 2-Amino-5-(phenoxymethyl)-2-oxazoline: Efficient Access to Bicyclic Pyrimidine Derivatives. <i>Synthesis</i> , 2007, 2007, 2193-2197.	1.2	0
360	Rapid and Efficient Microwave-Assisted Copper(0)-Catalyzed Ullmann Coupling Reaction: A General Access to Anilinoanthraquinone Derivatives. <i>Organic Letters</i> , 2007, 9, 1271-1274.	2.4	72

#	ARTICLE	IF	CITATIONS
361	Catalyst-Free Microwave-Assisted Amination of 2-Chloro-5-nitrobenzoic Acid. <i>Journal of Organic Chemistry</i> , 2007, 72, 5908-5911.	1.7	28
362	N <sup>9</sup> -Benzyl-substituted 1,3-dimethyl- and 1,3-dipropyl-pyrimido[2,1-f]purinediones: Synthesis and structure-activity relationships at adenosine A1 and A2A receptors. <i>Bioorganic and Medicinal Chemistry</i> , 2007, 15, 5003-5017.	1.4	34
363	Phenylethyl-substituted pyrimido[2,1-f]purinediones and related compounds: Structure-activity relationships as adenosine A1 and A2A receptor ligands. <i>Bioorganic and Medicinal Chemistry</i> , 2007, 15, 6956-6974.	1.4	35
364	Development and validation of a capillary electrophoresis method for the characterization of herpes simplex virus type 1 (HSV-1) thymidine kinase substrates and inhibitors. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2007, 846, 281-290.	1.2	23
365	Interaction of valerian extracts of different polarity with adenosine receptors: Identification of isovaltrate as an inverse agonist at A1 receptors. <i>Biochemical Pharmacology</i> , 2007, 73, 248-258.	2.0	44
366	Evaluation of anticonvulsant and analgesic effects of benzyl- and benzhydryl ureides. <i>European Journal of Pharmacology</i> , 2007, 559, 138-149.	1.7	14
367	Adenosine A2A receptor antagonism reverses the effects of dopamine receptor antagonism on instrumental output and effort-related choice in the rat: implications for studies of psychomotor slowing. <i>Psychopharmacology</i> , 2007, 191, 579-586.	1.5	93
368	Role of P2 purinergic receptors in synaptic transmission under normoxic and ischaemic conditions in the CA1 region of rat hippocampal slices. <i>Purinergic Signalling</i> , 2007, 3, 203-219.	1.1	38
369	[ <sup>3</sup> H]Adenine is a suitable radioligand for the labeling of G protein-coupled adenine receptors but shows high affinity to bacterial contaminations in buffer solutions. <i>Purinergic Signalling</i> , 2007, 3, 347-358.	1.1	7
370	A New Synthesis of Sulfonamides by Aminolysis of p-Nitrophenylsulfonates Yielding Potent and Selective Adenosine A2B Receptor Antagonists. <i>Journal of Medicinal Chemistry</i> , 2006, 49, 4384-4391.	2.9	50
371	Synthesis and Structure-Activity Relationships of Uracil Nucleotide Derivatives and Analogues as Agonists at Human P2Y2, P2Y4, and P2Y6 Receptors. <i>Journal of Medicinal Chemistry</i> , 2006, 49, 7076-7087.	2.9	109
372	Synthesis and preliminary evaluation of new 1- and 3-[1-(2-hydroxy-3-phenoxypropyl)]xanthines from 2-amino-2-oxazolines as potential A1 and A2A adenosine receptor antagonists. <i>Bioorganic and Medicinal Chemistry</i> , 2006, 14, 2697-2719.	1.4	21
373	Synthesis and pharmacology of pyrido[2,3-d]pyrimidinediones bearing polar substituents as adenosine receptor antagonists. <i>Bioorganic and Medicinal Chemistry</i> , 2006, 14, 2837-2849.	1.4	59
374	Synthesis and biological activity of tricyclic arylimidazo-, pyrimido-, and diazepinopurinediones. <i>Bioorganic and Medicinal Chemistry</i> , 2006, 14, 7258-7281.	1.4	36
375	Rapid microwave-assisted fluorination yielding novel 5-deoxy-5-fluorouridine derivatives. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2006, 16, 6139-6142.	1.0	15
376	Characterization of human and rodent native and recombinant adenosine A2B receptors by radioligand binding studies. <i>Purinergic Signalling</i> , 2006, 2, 559-571.	1.1	28
377	Polyoxometalates—a new class of potent ecto-nucleoside triphosphate diphosphohydrolase (NTPDase) inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2006, 16, 5943-5947.	1.0	167
378	Involvement of adenosine A2A and dopamine receptors in the locomotor and sensitizing effects of cocaine. <i>Brain Research</i> , 2006, 1077, 67-80.	1.1	90

#	ARTICLE	IF	CITATIONS
379	Development of off-line and on-line capillary electrophoresis methods for the screening and characterization of adenosine kinase inhibitors and substrates. <i>Electrophoresis</i> , 2006, 27, 2505-2517.	1.3	38
380	Improving Potency, Selectivity, and Water Solubility of Adenosine A <sub>1</sub> Receptor Antagonists: Xanthines Modified at Position 3 and Related Pyrimido[1,2,3-cd]purinediones. <i>ChemMedChem</i> , 2006, 1, 891-902.	1.6	54
381	P <sub>2</sub> Receptors Activated by Uracil Nucleotides - An Update. <i>Current Medicinal Chemistry</i> , 2006, 13, 289-312.	1.2	134
382	Microwave-assisted ring closure reactions: Synthesis of 8-substituted xanthine derivatives and related pyrimido- and diazepinopurinediones. <i>Beilstein Journal of Organic Chemistry</i> , 2006, 2, 20.	1.3	13
383	Recent Progress in the Development of Adenosine Receptor Ligands as Antiinflammatory Drugs. <i>Current Topics in Medicinal Chemistry</i> , 2006, 6, 1375-1399.	1.0	83
384	Synthesis of xanthine derivatives by microwave-assisted ring closure reaction. <i>Arkivoc</i> , 2006, 2006, 77-82.	0.3	0
385	Synthesis and preliminary evaluation of [ <sup>3</sup> H]PSB-0413, a selective antagonist radioligand for platelet P <sub>2</sub> Y <sub>12</sub> receptors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2005, 15, 5450-5452.	1.0	32
386	Role of central and peripheral adenosine receptors in the cardiovascular responses to intraperitoneal injections of adenosine A <sub>1</sub> and A <sub>2A</sub> subtype receptor agonists. <i>British Journal of Pharmacology</i> , 2005, 144, 642-650.	2.7	87
387	Involvement of adenosine A <sub>1</sub> receptors in the discriminative-stimulus effects of caffeine in rats. <i>Psychopharmacology</i> , 2005, 179, 576-586.	1.5	41
388	A detailed behavioral analysis of the acute motor effects of caffeine in the rat: involvement of adenosine A <sub>1</sub> and A <sub>2A</sub> receptors. <i>Psychopharmacology</i> , 2005, 183, 154-162.	1.5	67
389	Mass spectrometric identification of modified urinary nucleosides used as potential biomedical markers by LC-ITMS coupling. <i>Analytical and Bioanalytical Chemistry</i> , 2005, 382, 1017-1026.	1.9	58
390	A capillary electrophoresis method for the characterization of ecto-nucleoside triphosphate diphosphohydrolases (NTPDases) and the analysis of inhibitors by in-capillary enzymatic microreaction. <i>Purinergic Signalling</i> , 2005, 1, 349-358.	1.1	72
391	Evidence for the Functional Expression and Pharmacological Characterization of Adenine Receptors in Native Cells and Tissues. <i>Molecular Pharmacology</i> , 2005, 67, 955-964.	1.0	31
392	[ <sup>3</sup> H]BQ-123 Binding to Native Endothelin ET <sub>A</sub> Receptors in Human Astrocytoma 1321N1 Cells and Screening of Potential Ligands. <i>Pharmacology</i> , 2005, 74, 51-56.	0.9	4
393	Development of Spin-Labeled Probes for Adenosine Receptors. <i>Journal of Medicinal Chemistry</i> , 2005, 48, 2108-2114.	2.9	21
394	Lack of adenosine A <sub>1</sub> and dopamine D <sub>2</sub> receptor-mediated modulation of the cardiovascular effects of the adenosine A <sub>2A</sub> receptor agonist CGS 21680. <i>European Journal of Pharmacology</i> , 2004, 484, 269-275.	1.7	13
395	Tricyclic oxazolo[2,3-f]purinediones: potency as adenosine receptor ligands and anticonvulsants. <i>Bioorganic and Medicinal Chemistry</i> , 2004, 12, 4895-4908.	1.4	23
396	Imidazo[2,1-b]thiazepines: synthesis, structure and evaluation of benzodiazepine receptor binding. <i>European Journal of Medicinal Chemistry</i> , 2004, 39, 205-218.	2.6	19

#	ARTICLE	IF	CITATIONS
397	Novel Amino Acid Derived Natural Products from the Ascidian <i>Atriolum robustum</i> : Identification and Pharmacological Characterization of a Unique Adenosine Derivative. <i>Journal of Medicinal Chemistry</i> , 2004, 47, 2243-2255.	2.9	47
398	Antinociceptive Effects of Novel A2B Adenosine Receptor Antagonists. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2004, 308, 358-366.	1.3	144
399	Preparation, Properties, Reactions, and Adenosine Receptor Affinities of Sulfophenylxanthine Nitrophenyl Esters: A Toward the Development of Sulfonic Acid Prodrugs with Peroral Bioavailability. <i>Journal of Medicinal Chemistry</i> , 2004, 47, 1031-1043.	2.9	97
400	Multigram-Scale Syntheses, Stability, and Photoreactions of A2A Adenosine Receptor Antagonists with 8-Styrylxanthine Structure: A Potential Drugs for Parkinson's Disease. <i>Journal of Organic Chemistry</i> , 2004, 69, 3308-3318.	1.7	137
401	Extracellular metabolism of nucleotides in neuroblastoma x glioma NG108-15 cells determined by capillary electrophoresis. <i>Cellular and Molecular Neurobiology</i> , 2003, 23, 349-364.	1.7	23
402	Differential allosteric modulation by amiloride analogues of agonist and antagonist binding at A1 and A3 adenosine receptors. <i>Biochemical Pharmacology</i> , 2003, 65, 525-534.	2.0	54
403	Pyrimidin-8-on[2,1-f]theophylline-9-alkylcarboxylic acids amides as A1 and A2A adenosine receptor ligands. <i>Il Farmaco</i> , 2003, 58, 439-444.	0.9	3
404	Flavonoids - novel lead compounds for the development of P2Y2 receptor antagonists. <i>Drug Development Research</i> , 2003, 59, 72-81.	1.4	40
405	Versatile, convenient synthesis of pyrimido[1,2,3-cd]purinediones. <i>Tetrahedron</i> , 2003, 59, 47-54.	1.0	27
406	Impact of the aryl substituent kind and distance from pyrimido[2,1-f]purindiones on the adenosine receptor selectivity and antagonistic properties. <i>European Journal of Medicinal Chemistry</i> , 2003, 38, 397-402.	2.6	26
407	2-Phenylimidazo[2,1-i]purin-5-ones Structure-Activity relationships and characterization of potent and selective inverse agonists at Human A3 adenosine receptors. <i>Bioorganic and Medicinal Chemistry</i> , 2003, 11, 347-356.	1.4	51
408	Enabling role of adenosine A1 receptors in adenosine A2A receptor-mediated striatal expression of c-fos. <i>European Journal of Neuroscience</i> , 2003, 18, 296-302.	1.2	45
409	Effects of an adenosine A2A receptor blockade in the nucleus accumbens on locomotion, feeding, and prepulse inhibition in rats. <i>Synapse</i> , 2003, 49, 279-286.	0.6	53
410	Adenosine receptor agonists: from basic medicinal chemistry to clinical development. <i>Expert Opinion on Emerging Drugs</i> , 2003, 8, 537-576.	1.0	117
411	Involvement of Adenosine A1 and A2A Receptors in the Motor Effects of Caffeine after its Acute and Chronic Administration. <i>Neuropsychopharmacology</i> , 2003, 28, 1281-1291.	2.8	177
412	A Dual Role of Adenosine A <sub>2A</sub> Receptors in 3-Nitropropionic Acid-Induced Striatal Lesions: Implications for the Neuroprotective Potential of A <sub>2A</sub> Antagonists. <i>Journal of Neuroscience</i> , 2003, 23, 5361-5369.	1.7	118
413	Medicinal Chemistry of Adenosine A3 Receptor Ligands. <i>Current Topics in Medicinal Chemistry</i> , 2003, 3, 445-462.	1.0	104
414	Improved, Efficient Synthesis for Multigram-Scale Production of PSB-10, a Potent Antagonist at Human A3 Adenosine Receptors. <i>Heterocycles</i> , 2003, 60, 1425.	0.4	6



#	ARTICLE	IF	CITATIONS
415	Identification by Site-directed Mutagenesis of Residues Involved in Ligand Recognition and Activation of the Human A3 Adenosine Receptor. <i>Journal of Biological Chemistry</i> , 2002, 277, 19056-19063.	1.6	134
416	Imidazo[2,1-i]purin-5-ones and Related Tricyclic Water-Soluble Purine Derivatives: A Potent A2A- and A3-Adenosine Receptor Antagonists. <i>Journal of Medicinal Chemistry</i> , 2002, 45, 3440-3450.	2.9	81
417	1,8-Disubstituted Xanthine Derivatives: Synthesis of Potent A2B-Selective Adenosine Receptor Antagonists. <i>Journal of Medicinal Chemistry</i> , 2002, 45, 1500-1510.	2.9	134
418	Lignans Isolated from Valerian: Identification and Characterization of a New Olivil Derivative with Partial Agonistic Activity at A1 Adenosine Receptors. <i>Journal of Natural Products</i> , 2002, 65, 1479-1485.	1.5	143
419	P2-Pyrimidinerbic Receptors and Their Ligands. <i>Current Pharmaceutical Design</i> , 2002, 8, 2353-2369.	0.9	55
420	Interactions of valerian extracts and a fixed valerian hop extract combination with adenosine receptors. <i>Life Sciences</i> , 2002, 71, 1939-1949.	2.0	72
421	Metabotropic glutamate mGlu5 receptor-mediated modulation of the ventral striopallidal GABA pathway in rats. Interactions with adenosine A2A and dopamine D2 receptors. <i>Neuroscience Letters</i> , 2002, 324, 154-158.	1.0	124
422	[3H]8-Ethyl-4-methyl-2-phenyl-(8R)-4,5,7,8-tetrahydro-1H-imidazo[2,1-i]-purin-5-one ([3H]PSB-11), a Novel High-Affinity Antagonist Radioligand for Human A3 Adenosine Receptors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2002, 12, 501-503.	1.0	92
423	Fast, efficient capillary electrophoresis method for measuring nucleotide degradation and metabolism. <i>Journal of Chromatography A</i> , 2002, 952, 275-281.	1.8	38
424	Synthesis of 8-Substituted Xanthine Derivatives by Suzuki Cross-Coupling Reaction. <i>Heterocycles</i> , 2002, 57, 871.	0.4	21
425	Structure-Activity Relationships at Human and Rat A2B Adenosine Receptors of Xanthine Derivatives Substituted at the 1-, 3-, 7-, and 8-Positions. <i>Journal of Medicinal Chemistry</i> , 2002, 45, 2131-2138.	2.9	76
426	Adenosine/dopamine interaction: implications for the treatment of Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2001, 7, 235-241.	1.1	118
427	Allosteric Modulation of A3 Adenosine Receptors by a Series of 3-(2-Pyridinyl)isoquinoline Derivatives. <i>Molecular Pharmacology</i> , 2001, 60, 1057-1063.	1.0	82
428	New developments in A1 and A2 adenosine receptor antagonists. <i>Pure and Applied Chemistry</i> , 2001, 73, 1411-1420.	0.9	33
429	Imidazo-thiazine, -diazinone and -diazepinone derivatives. Synthesis, structure and benzodiazepine receptor binding. <i>European Journal of Medicinal Chemistry</i> , 2001, 36, 407-419.	2.6	38
430	Catalepsy induced by a blockade of dopamine D1 or D2 receptors was reversed by a concomitant blockade of adenosine A2A receptors in the caudate-putamen of rats. <i>European Journal of Neuroscience</i> , 2001, 14, 1287-1293.	1.2	100
431	A1 adenosine receptors and their ligands: overview and recent developments. <i>Il Farmaco</i> , 2001, 56, 77-80.	0.9	43
432	A Novel Ring Closure Reaction for the Preparation of 6-Aminouracils with an $\alpha$ -Branched 1-Substituent. <i>Heterocycles</i> , 2000, 53, 347.	0.4	11

#	ARTICLE	IF	CITATIONS
433	Electrophysiological and behavioural evidence for an antagonistic modulatory role of adenosine A2A receptors in dopamine D2 receptor regulation in the rat dopamine-denervated striatum. <i>European Journal of Neuroscience</i> , 2000, 12, 4033-4037.	1.2	82
434	Binding of [3H]MSX-2 (3-(3-hydroxypropyl)-7-methyl-8-(m-methoxystyryl)-1-propargylxanthine) to rat striatal membranes: a new, selective antagonist radioligand for A2A adenosine receptors. <i>European Journal of Pharmaceutical Sciences</i> , 2000, 10, 259-265.	1.9	80
435	Adenosine Receptor Ligands-Recent Developments Part I. Agonists. <i>Current Medicinal Chemistry</i> , 2000, 7, 1269-1288.	1.2	89
436	Development Assay for of a 5-Hydroxytryptamine2A Receptor Binding High Throughput Screening Using 96-Well Microfilter Plates. <i>Journal of Biomolecular Screening</i> , 2000, 5, 269-277.	2.6	8
437	Water-Soluble Phosphate Prodrugs of 1-Propargyl-8-styrylxanthine Derivatives, A2A-Selective Adenosine Receptor Antagonists. <i>Journal of Medicinal Chemistry</i> , 2000, 43, 440-448.	2.9	129
438	7-Deazaadenines Bearing Polar Substituents: Structure-Activity Relationships of New A1 and A3 Adenosine Receptor Antagonists. <i>Journal of Medicinal Chemistry</i> , 2000, 43, 4636-4646.	2.9	49
439	A2A adenosine receptor antagonists - future drugs for Parkinson's disease?. <i>Drugs of the Future</i> , 2000, 25, 1043.	0.0	55
440	5-Substituted UTP derivatives as P2Y2 receptor agonists. <i>European Journal of Medicinal Chemistry</i> , 1999, 34, 809-824.	2.6	22
441	Arylidene imidazothiazoles. Synthesis, structure and benzodiazepine receptor binding. <i>Journal of Heterocyclic Chemistry</i> , 1999, 36, 257-263.	1.4	9
442	1-Substituted 4-[Chloropyrazolyl][1,2,4]triazolo[4,3-a]quinoxalines: Synthesis and Structure-Activity Relationships of a New Class of Benzodiazepine and Adenosine Receptor Ligands. <i>Archiv Der Pharmazie</i> , 1998, 331, 163-169.	2.1	15
443	A2A-selective adenosine receptor antagonists: Development of water-soluble prodrugs and a new tritiated radioligand. <i>Drug Development Research</i> , 1998, 45, 190-197.	1.4	22
444	8-(Sulfostyryl)xanthines: water-soluble A2A-selective adenosine receptor antagonists Preliminary results were presented at the International Symposium "Purines" in Milan, Italy; abstract published in <i>Drug Dev. Res.</i> 1996, 37, 112.. <i>Bioorganic and Medicinal Chemistry</i> , 1998, 6, 707-719.	1.4	46
445	Bioactive Pyridoacridine Alkaloids from the Micronesian Sponge <i>Oceanapia</i> sp.. <i>Journal of Natural Products</i> , 1998, 61, 301-305.	1.5	63
446	Synthesis of Paraxanthine and Isoparaxanthine Analogs (1,7- and 1,9-Substituted Xanthine Derivatives). <i>Synthesis</i> , 1998, 1998, 1428-1436.	1.2	10
447	Motor effects induced by a blockade of adenosine A2A receptors in the caudate-putamen. <i>NeuroReport</i> , 1998, 9, 1803-1806.	0.6	66
448	Synthesis and Structure-Activity Relationships of 3,7-Dimethyl-1-propargylxanthine Derivatives, A2A-Selective Adenosine Receptor Antagonists. <i>Journal of Medicinal Chemistry</i> , 1997, 40, 4396-4405.	2.9	82
449	Configurational stable analogs of styrylxanthines as A2A adenosine receptor antagonist. <i>European Journal of Medicinal Chemistry</i> , 1997, 32, 709-719.	2.6	25
450	A1-Adenosine receptor antagonists. <i>Expert Opinion on Therapeutic Patents</i> , 1997, 7, 419-440.	2.4	72

#	ARTICLE	IF	CITATIONS
451	Uridine nucleotide receptors and their ligands: structural, physiological, and pathophysiological aspects, with special emphasis on the nervous system. <i>Neurochemical Research</i> , 1997, 22, 1041-1050.	1.6	16
452	Aza-Analogs of 8-Styrylxanthines as A2A-Adenosine Receptor Antagonists. <i>Archiv Der Pharmazie</i> , 1997, 330, 181-189.	2.1	18
453	Chiral Pyrrolo[2,3-d]pyrimidine and Pyrimido[4,5-b]indole Derivatives: Structure-Activity Relationships of Potent, Highly Stereoselective A1-Adenosine Receptor Antagonists. <i>Journal of Medicinal Chemistry</i> , 1996, 39, 2482-2491.	2.9	35
454	A New Versatile Synthesis of Xanthines with Variable Substituents in the 1-, 3-, 7- and 8-Positions. <i>Synthesis</i> , 1995, 1995, 1295-1299.	1.2	31
455	Formation of 7,9-Disubstituted Xanthinium Compounds Under Mild Conditions by Alkylation of Silylated Xanthines. <i>Synthetic Communications</i> , 1994, 24, 1311-1315.	1.1	1
456	Synthesis and Structure-Activity Relationships of Deazaxanthines: Analogs of Potent A1- and A2-Adenosine Receptor Antagonists. <i>Journal of Medicinal Chemistry</i> , 1994, 37, 1526-1534.	2.9	64
457	Stimulation of calcium release by caffeine analogs in pheochromocytoma cells. <i>Biochemical Pharmacology</i> , 1993, 46, 1825-1829.	2.0	24
458	Adenosine receptors and their modulators. <i>Pharmaceutica Acta Helveticae</i> , 1993, 68, 77-111.	1.2	115
459	General Synthesis and Properties of 1-Monosubstituted Xanthines. <i>Synthesis</i> , 1993, 1993, 125-128.	1.2	28
460	Synthesis of 3-substituted 6-aminouracils. <i>Tetrahedron Letters</i> , 1991, 32, 6539-6540.	0.7	41
461	Caffeine Analogs: Structure-Activity Relationships at Adenosine Receptors. <i>Pharmacology</i> , 1991, 42, 309-321.	0.9	62
462	A new synthesis of thiophosphoric acid esters with a C-S-P bond. <i>Tetrahedron Letters</i> , 1990, 31, 501-502.	0.7	19
463	Amphiphile unsymmetrische Disulfide als Liposomenbausteine. <i>Archiv Der Pharmazie</i> , 1989, 322, 343-350.	2.1	9
464	Lipophilic disulfide prodrugs synthesis and disulfide bond cleavage. <i>International Journal of Pharmaceutics</i> , 1989, 57, 41-47.	2.6	5
465	Eine einzige stabilisierende Punktmutation ermöglicht hochaufgelöste Co-Kristallstrukturen des Adenosin-2A-Rezeptors mit Preladenant-Konjugaten. <i>Angewandte Chemie</i> , 0, , .	1.6	0